← All companies

KZIA

Kazia Therapeutics Limited

KZIA Nasdaq Pharmaceutical Preparations EDGAR ↗

$12.41

-0.21 -1.66%

Key statistics

from XBRL data in SEC filings

Market cap

$10.0B

Revenue (TTM)

—

Net income (TTM)

—

EPS (TTM)

—

P/E ratio

—

Dividend yield

—

Free cash flow

—

Cash

—

Total assets

—

Gross margin

—

52-week range

$4.86 – $17.40

Recent SEC filings

40 most recent

Annual, quarterly & current reports

6-K REPORT OF FOREIGN PRIVATE ISSUER Jul 28, 2026 6-K REPORT OF FOREIGN PRIVATE ISSUER Jun 2, 2026 6-K REPORT OF FOREIGN PRIVATE ISSUER May 26, 2026 6-K REPORT OF FOREIGN PRIVATE ISSUER Apr 27, 2026 6-K REPORT OF FOREIGN PRIVATE ISSUER Apr 15, 2026 6-K REPORT OF FOREIGN PRIVATE ISSUER Apr 13, 2026 6-K REPORT OF FOREIGN PRIVATE ISSUER Mar 31, 2026 6-K REPORT OF FOREIGN PRIVATE ISSUER Mar 30, 2026 6-K Mar 19, 2026 6-K Jan 27, 2026 6-K Dec 19, 2025 6-K Dec 10, 2025 6-K Dec 5, 2025 6-K Dec 2, 2025 6-K Nov 18, 2025 20-F Nov 7, 2025 6-K Oct 7, 2025 6-K FORM 6-K Oct 2, 2025 6-K Sep 11, 2025 6-K Aug 1, 2025 6-K Jul 25, 2025 6-K Jul 9, 2025 6-K FORM 6-K Jun 11, 2025 6-K Jun 10, 2025 6-K FORM 6-K Jun 5, 2025 6-K FORM 6-K May 28, 2025 6-K FORM 6-K May 15, 2025 6-K FORM 6-K Apr 15, 2025 6-K Mar 31, 2025 6-K Mar 13, 2025 6-K Feb 20, 2025 6-K Feb 3, 2025 6-K Jan 30, 2025 6-K Jan 13, 2025 6-K Dec 31, 2024 6-K Dec 11, 2024 20-F FORM 20-F Nov 15, 2024 6-K Nov 12, 2024 6-K Nov 4, 2024 6-K/A Oct 24, 2024